Cyxone reports publication of four patent applications pertaining to its drug candidate Rabeximod
Cyxone (publ) today announces that four patent applications pertaining to its drug candidate Rabeximod have been published by the PCT authority (WIPO). If approved, these patents have potential to prolong the market exclusivity of Rabeximod until 2041.
The four patent applications published by the PCT authority (WIPO) are:
[A] PCT/EP2021/065705 New Oral Formulation (this patent if granted is expected to give good protection for oral formulation of Rabeximod in crystalline form)
[B] PCT/EP2021/065693 New Use of Rabeximod (this patent if granted is expected to give good protection for use of Rabeximod in any form for treatment of a pathogenic infection and acute respiratory syndromes)
[C] PCT/EP2021/065697 Rabeximod in treatment of RA (this patent if granted is expected to give good protection for use of Rabeximod in treating any stage of RA)
[D] PCT/EP2021/065694 Large Scale Process (this patent if granted is expected to give good protection for the process for manufacturing Rabeximod)
“The four patent applications - covering a range of areas such as therapeutic use of Rabeximod, the process of manufacturing our drug compound and the drug formulation - are important value drivers for Rabeximod and for Cyxone. Together with the new patent application filed this month on new forms of Rabeximod Cyxone has a strong and extended patent protection if the patents are awarded. By reinforcing the intellectual property of our unique drug candidate Rabeximod, and extending the patent lifetime, we ensure the ability to develop Rabeximod for RA and other indications in autoimmune disease and neuroinflammation. They will allow us time and scope to exploit the full potential of Rabeximod,” comments Tara Heitner, CEO, Cyxone.
Tara Heitner, CEO
Tel: +46 70 781 88 08
211 22 Malmö, Sweden
Cyxone AB (publ) (Nasdaq First North Growth Market: CYXO) develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis as well as treatments for virally induced acute respiratory disorders. Rabeximod is a Phase 2 candidate drug being evaluated for the management of rheumatoid arthritis and moderate Covid-19 infections. T20K is a Phase 1 candidate drug for treatment of multiple sclerosis. Certified Adviser is FNCA Sweden AB, +46(0)8-528 00 399, email@example.com. For more information, please visit www.cyxone.comOpen Press release